FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Diseases patents



      
           
This page is updated frequently with new Diseases-related patent applications. Subscribe to the Diseases RSS feed to automatically get the update: related Diseases RSS feeds. RSS updates for this page: Diseases RSS RSS


Devices and methods for treatment of vascular aneurysms

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through,…

Delivery system, method, and anchor for medical implant placement

Date/App# patent app List of recent Diseases-related patents
07/24/14
20140208464
 Delivery of viral agents patent thumbnailDelivery of viral agents
Plant material has bacteriophage has been attached, wherein the bacteriophage retains infectivity. The plant material includes fruits, vegetables, leaves, stems, flowers, roots, tubers, seedlings and seeds.
07/24/14
20140207226
 Devices and methods for treatment of vascular aneurysms patent thumbnailDevices and methods for treatment of vascular aneurysms
The present invention relates to devices and methods for the treatment of diseases in the vasculature, and more specifically, devices and methods for treatment of aneurysms found in blood vessels. In a first embodiment of the present invention, a two part prostheses, where one part is an expandable sponge structure and the other part is an expandable tubular mesh structure, is provided.
07/24/14
20140207220
 Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism patent thumbnailImplantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.
07/24/14
20140207153
 Delivery system, method, and anchor for medical implant placement patent thumbnailDelivery system, method, and anchor for medical implant placement
A delivery system and method for placing a medical implant, such as for diagnosing, monitoring and/or treating cardiovascular diseases. The delivery system includes a hollow catheter, an anchor coupled to the catheter, and an implant secured within the anchor.
07/24/14
20140207003
 Systems and methods for detection of disease including oral scopes and ambient light management systems (alms) patent thumbnailSystems and methods for detection of disease including oral scopes and ambient light management systems (alms)
Methods and systems related to detecting disease, such as oral cancer, in a patient, using a viewing scope to investigate a patient's tissues. The systems and methods excite and detect fluorescence from the tissue.
07/24/14
20140206986
 Optical capsule and spectroscopic method for treating and diagnosing the intestinal tract patent thumbnailOptical capsule and spectroscopic method for treating and diagnosing the intestinal tract
A device and method for mapping, diagnosing and treating disorders or other diseases, disorders or conditions (e.g., bleeding, ischemic or necrotic tissue, and presence of certain chemicals or substances) of the intestinal tract is provided using a capsule passing through the intestinal tract and sensing optical characteristics as the capsule passes through. Further, a capsule tracking system is provided for tracking a capsule's location along the length of an intestinal tract as various treatment and/or sensing modalities are employed.
07/24/14
20140206879
 Dipeptoid prodrugs and their use patent thumbnailDipeptoid prodrugs and their use
The present application relates to prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.. .
07/24/14
20140206876
 2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists patent thumbnail2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists
Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/24/14
20140206865
 Human adam-10 inhibitors patent thumbnailHuman adam-10 inhibitors
The present invention provides compounds useful for inhibiting the adam-10 protein, with selectivity versus mmp-1. Such compounds are useful in the in vitro study of the role of adam-10 (and its inhibition) in biological processes.
07/24/14
20140206853
 Targeted binding agents directed to dll4 and uses thereof patent thumbnailTargeted binding agents directed to dll4 and uses thereof
The invention relates to targeted binding agents against dll4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to dll4.
07/24/14
20140206771
Liquid pharmaceutical composition comprising nitisinone
The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a ph in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (hppd) is desirable, e.g.
07/24/14
20140206768
Choline salt of an anti-inflammatory substituted cyclobutenedione compound
6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-n-methoxy-n-methyl-benzenesulfonamide choline, solid pharmaceutical compositions and oral dosage forms that contain said compound, and a method of using such compositions and oral dosage forms to treat people who have inflammatory, obstructive or allergic conditions and diseases are disclosed.. .
07/24/14
20140206762
Compositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease.
07/24/14
20140206753
Lipid nanoparticle compositions and methods for mrna delivery
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies..
07/24/14
20140206749
Targeting the steroidogenic pathway for treating and/or preventing allergic diseases
The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.. .
07/24/14
20140206747
Compositions and methods for inhibiting expression of factor v
The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of factor v, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of factor v. The invention also relates to a pharmaceutical composition comprising the dsrna together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of factor v using the pharmaceutical composition; and methods for inhibiting the expression of factor v in a cell..
07/24/14
20140206739
Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds.
07/24/14
20140206734
Serotonin transporter gene and treatment of alcoholism
The gene responsible for encoding sert has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (l) and short (s). The ll-genotype is hypothesized to play a key role in the early onset of alcohol use.
07/24/14
20140206732
Compositions and methods of treatment of inflammatory skin conditions using allantoin
Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof.
07/24/14
20140206731
Composition and method for controlling plant diseases
The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising an amide compound represented by a formula (i); wherein each of symbols are the same as defined in the description; or salts thereof and at least one kind of azole compounds selected from the group (a) consisting of tebuconazole, difenoconazole, triticonazole, imazalil, triadimenol, fluquinconazole, prochloraz, prothioconazole, diniconazole, diniconazole m, cyproconazole, tetraconazole, ipconazole, triforine, pyrifenox, fenarimol, nuarimol, oxpoconazole fumarate, pefurazoate, triflumizole, azaconazole, bitertanol, bromuconazole, epoxiconazole, fenbuconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, myclobutanil, penconazole, propiconazole, simeconazole, triadimefon and metconazole, shows an excellent controlling efficacy on plant diseases..
07/24/14
20140206730
Composition and method for controlling plant diseases
The present invention provides a composition for controlling plant diseases having an excellent control efficacy on plant diseases. A composition for controlling plant diseases comprising an amide compound represented by a formula (i): wherein each of symbols are the same as defined in the description; or salts thereof and one or more kinds of azole compounds selected from the group (a) consisting of tebuconazole, difenoconazole, triticonazole, imazalil, triadimenol, fluquinconazole, prochloraz, prothioconazole, diniconazole, diniconazole m, cyproconazole, tetraconazole, ipconazole, triforine, pyrifenox, fenarimol, nuarimol, oxpoconazole fumarate, pefurazoate, triflumizole, azaconazole, bitertanol, bromuconazole, epoxiconazole, fenbuconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, myclobutanil, penconazole, propiconazole, simeconazole, triadimefon and metconazole, shows an excellent controlling efficacy on plant diseases..
07/24/14
20140206724
Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206723
Methods for treating amyloidosis with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
07/24/14
20140206721
Method to predict response to pharmacological chaperone treatment of diseases
The present invention provides methods to determine whether a patient with a lysosomal storage disorder win benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase a responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase a.
07/24/14
20140206715
Preparation and use of compounds as protease inhibitors
And r, r1, r2, r3, r4, r5, r6, r6, r7 and r7′ are as defined in the specification; pharmaceutical compositions comprising the compounds of formula i and the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases.. .
07/24/14
20140206711
Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
07/24/14
20140206694
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
07/24/14
20140206689
Modulators of atp-binding cassette transporters
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator (“cftr”). The present invention also relates to methods of treating abc transporter mediated diseases using compounds of the present invention..
07/24/14
20140206685
Heterocyclic kinase inhibitors
The present invention provides heterocyclic compounds for use as kinase inhibitors and in other applications. Also provided are pharmaceutical compositions and methods of treatments of diseases and conditions associated with p13 kinase activity..
07/24/14
20140206684
Certain chemical entities, compositions and methods
Chemical entities that modulate pi3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with p13 kinase activity are described herein.. .
07/24/14
20140206683
Macrocyclic lrrk2 kinase inhibitors
The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of lrrk2 (leucine-rich repeat kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by lrrk2 kinase activity such as neurological disorders including parkinson's disease and alzheimer's disease..
07/24/14
20140206682
Compounds and compositions as pdgfr kinase inhibitors
The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of pdgfr (pdgfrα, pdgfrβ) kinases or c-kit and pdgfr (pdgfrα, pdgfrβ) kinases..
07/24/14
20140206680
Substituted 6-aza-isoindolin-1-one derivatives
Disclosed are compounds of formula 1, and pharmaceutically acceptable salts thereof, wherein g, p, r1, r2, r3a, r4, and r5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, cancer, and other disorders, diseases, and conditions for which inhibition of syk is indicated..
07/24/14
20140206679
Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
The present invention relates to a heterocyclic pyridone compound represented by general formula (i), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method.
07/24/14
20140206672
Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are thiophenyl and pyrrolyl azepine compounds.
07/24/14
20140206665
Selective glycosidase inhibitors and uses thereof
The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of o-glcnacase, and/or accumulation or deficiency of o-glcnac.. .
07/24/14
20140206660
Phenyl-heteroaryl derivatives and methods of use thereof
The present invention further relates to methods for the preparation of compounds of formula (i) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating rage-mediated diseases.. .
07/24/14
20140206658
Seleno-compounds and therapeutic uses thereof
The present invention relates to compounds and compositions useful as antioxidants and in particular to selenium containing compounds of formula (i): wherein n is 1, 2, or 3; m is 2, 3, 4, or 5; and each r] is independently —(optionally substituted c1-c3 alkylene) p-oh, where p is 0 or 1, or a salt thereof. The invention also relates to the use of these seleno-compounds in the treatment of diseases or conditions associated with increased levels of oxidants produced by myeloperoxidase (mpo), such as for instance, atherosclerosis..
07/24/14
20140206645
Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase
Disclosed herein are novel compounds of formula (i), and uses thereof. The compounds of formula (i) are inhibitors of histone deacetylases (hdacs) and 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase (hmgr).
07/24/14
20140206641
Remedy
It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis.
07/24/14
20140206640
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
The present invention relates to 2′-azido substituted nucleoside derivatives of formula (i): and pharmaceutically acceptable salts thereof, wherein b, x, r1, r2 and r3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-azido substituted nucleoside derivative, and methods of using the 2′-azido substituted nucleoside derivatives for treating or preventing hcv infection in a patient..
07/24/14
20140206634
Natural composition to decrease effects of a high fat diet
The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable.
07/24/14
20140206625
Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
07/24/14
20140206618
Inhibitors of the renal outer medullary potassium channel
The present invention provides compounds of formula ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention..
07/24/14
20140206615
Glp-1 agonist and cardiovascular complications
Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a glp-1 agonist.. .
07/24/14
20140206556
Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.. .
07/24/14
20140206549
Method of measuring adaptive immunity
A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it.
07/24/14
20140206548
Method of measuring adaptive immunity
A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it.
07/24/14
20140206061
Bioactive carbon nanotube composite functionalized with b-sheet polypeptide block copolymer, and preparation method thereof
The present invention relates to a bioactive carbon nanotube composite functionalized with a β-sheet polypeptide block copolymer by combination self-assembly, which shows excellent water dispersion, and has biological activity so as to be used as stimulus-responsive and adaptable biomaterials or in the manufacture of cnt-based electronic biosensor devices. In addition, the bioactive carbon nanotube composite can be used as a composition for delivery of a biological active material into cells.
07/24/14
20140206028
Stable electrically active neurons from adult tissue
Disclosed are compositions and methods of making stable electrically active adult neurons from adult neural tissue. The disclosed compositions can be used with microelectrode arrays in vitro to represent in vivo neural function for drug discovery and for studying neuronal degenerative diseases, neuronal development, and neuronal regeneration..
07/24/14
20140206004
Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays
This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics.
07/24/14
20140205693
Bacterial extract for respiratory disorders and process for its preparation
The present invention relates to an extract from bacterial strains, such as staphylococcus, moraxella, klebsiella, streptococcus, and haemophilus. The extract is useful as a treatment for indications such as respiratory disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases..
07/24/14
20140205687
Tribulus terrestris, avena sativa and panax ginseng extract combination
The present invention, is related to a herbal pharmaceutical product, obtained from the defined parts of the tribulus terrestris, avena sativa and panax ginseng plants, in order to be used as a supplement and support to increase muscle strength, body stamina and physical performance and in order to treat cardiovascular diseases and the present invention is also related to the formulation of said product.. .
07/24/14
20140205662
System and method for differentially timed local delivery of a combination pharmaceutical preparation for oral therapy
The present invention is directed to a system and method for treating oral diseases in a subject. This method comprises the following steps; diagnosing the subject, and choosing one or a combination of medications, their dosing and desired time course and then delivering the medications to the desired site in the periodontal pocket by administering a plurality of microcapsules, capsules, the microcapsules comprising one or more pharmaceutical agent(s) that are released in a predetermined manner and in accordance with the pathophysiology of the targeted disease..
07/24/14
20140205632
Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles
The present invention relates to compositions of virus-like particles for the introduction of rna-interference (rnai-) inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with rnai-inducing molecules. The present invention furthermore relates to methods for a diagnosis, prevention and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids..
07/24/14
20140205620
Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
Highly antigenic yet safe vaccines against diseases caused by paramyxoviridae viruses such as respiratory syncytial virus (rsv) are provided. The vaccines comprise attenuated paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (m) protein.
07/24/14
20140205611
Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
Disclosed herein are anti-hgm-csf monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hgm-csf activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided.
07/24/14
20140205610
Anti-folr1 antibody
The present invention provides an anti-human folr1 antibody against diseases associated with human folr1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human folr1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (adcc activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human folr1 or the conformational structure thereof and also has adcc activity and cdc activity, or an antibody fragment thereof, a dna encoding the antibody, a vector comprising the dna, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient..
07/24/14
20140205604
Antigen binding constructs
The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain fc region of an antibody, wherein each epitope binding domain in capable of binding to vegf, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with vegf signalling, such as diabetic macular edema (dme), wet age-related macular degeneration (wet amd). Diabetic retinopathy, retinal vein occlusion (rvo), and corneal neovascularisation, and polynucleotide sequences encoding said antigen binding constructs..
07/24/14
20140205603
Siglec-15 antibodies in treating bone loss-related disease
Novel antibodies and antigen binding fragments that specifically binds to siglec-15 are described herein in some embodiments, the antibodies or antigen binding fragments may block the biological activity of siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts the invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.. .
07/24/14
20140205602
Antagonist anti-cd40 monoclonal antibodies and methods for their use
Compositions and methods of therapy for treating diseases mediated by stimulation of cd40 signaling on cd40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-cd40 antibody or antigen-binding fragment thereof to a patient in need thereof.
07/24/14
20140205601
Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
The present invention relates to amino acid sequences that are directed against rank-l, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes..
07/24/14
20140205600
Methods of promoting fat loss comprising administering an alk7 inhibitor
The invention relates to alk7 soluble receptors and their uses as antagonists of the function of certain ligands such as gdf-8 (myostatin) and gdf-11. The alk7 soluble receptor of the invention is useful as antagonists of gdf-8 and gdf-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases.
07/24/14
20140205599
Polypeptide that binds aberrant cells and induces apoptosis
Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an mhc-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes.
07/24/14
20140205596
Organic compounds
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer..
07/24/14
20140205576
Methods and compositions for increased transgene expression
Described herein are methods of expressing nucleic acids in t cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-cd3 and anti-cd28 antibodies and the adenoviral vector is pseudotyped for t-cell entry.
07/24/14
20140205570
Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
The subject invention pertains to the use of fractalkine (fkn, cx3cl1) and its receptor cx3cr1 for treatment of neuroinflammation and/or neurodegeneration. In one embodiment, the present invention provides a method for treatment of neuroinflammation and/or neurodegenerative diseases, comprising: administering, to cells of a subject in need of such treatment, an adeno-associated virus that comprises a functional fractalkine gene operably linked to transcriptional control elements.
07/24/14
20140205563
Compositions derived from stem cell released molecules & methods for formulation thereof
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (srm's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and srm's can be derived from one or more distinct cell lines.
07/24/14
20140205541
Method for detection of characteristics of organ fibrosis
The disclosed invention is a method for detecting indications of the presence of liver disease and other fibrotic diseases using a magnetic-resonance based technique for measuring fine tissue and bone textures. Specifically, the invention focuses on adaptations to this prior art to facilitate assessment of the presence and severity of liver disease, lung disease, and other fibrotic disease by measuring spatial wavelengths characteristic of the specific disease process across an areal cross-section through an organ.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



1.9905

4097

71 - 0 - 89